S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Karyopharm Therapeutics Stock Price, News & Analysis (NASDAQ:KPTI)

$0.86
+0.02 (+2.38%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.84
$0.88
50-Day Range
$0.68
$1.34
52-Week Range
$0.67
$4.87
Volume
731,389 shs
Average Volume
2.28 million shs
Market Capitalization
$98.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.86

Karyopharm Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
581.1% Upside
$5.86 Price Target
Short Interest
Bearish
16.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.92mentions of Karyopharm Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$50,191 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.13) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

509th out of 954 stocks

Biotechnology Industry

52nd out of 109 stocks


KPTI stock logo

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Stock Price History

KPTI Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Karyopharm Therapeutics (NASDAQ: KPTI)
Dozens more biotech jobs axed as two firms make cuts
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
385
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.86
High Stock Price Target
$10.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+579.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-165,290,000.00
Pretax Margin
-95.64%

Debt

Sales & Book Value

Annual Sales
$145.87 million
Book Value
($0.15) per share

Miscellaneous

Free Float
110,731,000
Market Cap
$98.72 million
Optionable
Optionable
Beta
-0.18
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Richard A. Paulson M.B.A. (Age 56)
    President, CEO & Director
    Comp: $1.36M
  • Dr. Sharon Shacham M.B.A. (Age 53)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
    Comp: $1.4M
  • Mr. Michael P. Mason CPAMr. Michael P. Mason CPA (Age 48)
    M.B.A., Executive VP, CFO & Treasurer
    Comp: $681.59k
  • Mr. Michael J. Mano J.D. (Age 46)
    Senior VP, General Counsel & Secretary
    Comp: $625.08k
  • Ms. Sohanya Cheng M.B.A. (Age 40)
    Executive VP & Chief Commercial Officer
    Comp: $664.3k
  • Mr. Stuart Poulton
    Executive VP & Chief Development Officer
  • Dr. Mansoor Raza Mirza M.D. (Age 62)
    Clinical Consultant, Member of Scientific Advisory Board & Independent Director
    Comp: $150k
  • Mr. Cameron Peters (Age 63)
    Vice President of Finance, Assistant Treasurer & Principal Accounting Officer
  • Ms. Elhan Webb C.F.A.
    Senior Vice President of Investor Relations
  • Mr. James Accumanno J.D.
    Chief Compliance Officer














KPTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KPTI shares.
View KPTI analyst ratings
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price target for 2024?

6 brokers have issued 1-year target prices for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they predict the company's stock price to reach $5.86 in the next year. This suggests a possible upside of 581.1% from the stock's current price.
View analysts price targets for KPTI
or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2023?

Karyopharm Therapeutics' stock was trading at $3.40 on January 1st, 2023. Since then, KPTI shares have decreased by 74.7% and is now trading at $0.86.
View the best growth stocks for 2023 here
.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our KPTI earnings forecast
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The firm earned $36.01 million during the quarter, compared to analyst estimates of $37.34 million.

What ETF holds Karyopharm Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (7.25%), Jacobs Levy Equity Management Inc. (2.05%), Barclays PLC (1.01%), Tejara Capital Ltd (0.94%), Tejara Capital Ltd (0.94%) and Northern Trust Corp (0.86%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton.
View institutional ownership trends
.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KPTI) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -